Modelling the impact of detecting and treating carcinoma in situ in a breast screening programme

Journal of Medical Screening

Volumn 11, Issue 3, 2004, Pages 117-125

  McCann, Jenny ^b   Treasure, Peter ^b   Duffy, Stephen ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST EXAMINATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER INVASION; CANCER MODEL; CANCER SCREENING; CARCINOMA IN SITU; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; REGRESSION ANALYSIS;

AGED; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL; ENGLAND; FEMALE; HUMANS; INCIDENCE; MASS SCREENING; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM INVASIVENESS; POISSON DISTRIBUTION; STATE MEDICINE;

EID: 4644302182     PISSN: 09691413     EISSN: None     Source Type: Journal    
DOI: 10.1258/0969141041732201     Document Type: Article

References (52)

1. Ernster VL, Barclay J, Kerlikowske K, et al. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 1996;275:913-8.
2. Feig SA. Ductal carcinoma in situ. Implications for screening mammography. Radiol Clin North Am 2000;38:653-68, vii.
3. Barchielli A., Paci E., Giorgi D. Recent trends of in situ carcinoma of the breast and mammographic screening in the Florence area, Italy. Cancer Causes Control 1999;10:313-7.
4. Holland R, Hendriks JH, Vebeek AL, et al. Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet 1990;335:519-22.
5. Millikan R, Dressler L, Geradts J, et al. The need for epidemiologic studies of in-situ carcinoma of the breast. Breast Cancer Res Treat 1995;35:65-77.
6. Sakorafas GH, Tsiotou AG. Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives. Cancer Treat Rev 2000;26:103-25.
7. Betsill WL, Jr., Rosen PP, Lieberman PH, et al. Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone. JAMA 1978;239:1863-7.
8. Eusebi V, Feudale E, Foschini MP, et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol 1994;11:223-35.
9. Farrow JH. Current concepts in the detection and treatment of the earliest of the early breast cancers. Cancer 1970;25:468-77.
10. Page DL, Dupont WD, Rogers LW, et al. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 1982;49:751-8.
11. Page DL, Dupont WD, Rogers LW, et al. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 1995;76:1197-200.
12. Rosen PP, Braun DW, Jr., Kinne DE. The clinical significance of preinvasive breast carcinoma. Cancer 1980;46:919-25.
13. Ottesen GL, Graversen HP, Blichert-Toft M, et al. Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study. Breast Cancer Res Treat 2000;62:197-210.
14. Alpers CE, Wellings SR. The prevalence of carcinoma in situ in normal and cancer-associated breasts. Hum Pathol 1985;16:790-807.
15. Bartow SA, Pathak DR, Black WC, et al. Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. A forensic autopsy study. Cancer 1987;60:2751-60.
16. Bhathal PS, Brown RW, Lesueur GC, et al. Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women. Br J Cancer 1985;51:271-8.
17. Nielsen M, Jensen J, Andersen J. Precancerous and cancerous breast lesions during lifetime and at autopsy. A study of 83 women. Cancer 1984;54:612-5.
18. Nielsen M, Thomsen JL, Primdahl S, et al. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer 1987;56:814-9.
19. Cady B. How to prevent invasive breast cancer: detect and excise duct carcinoma in situ. J Surg Oncol 1998;69:60-2.
20. Baum M. Review: ABC of Breast Disease. J Med Screen 1995;2:233-4.
21. Rakovitch E, Franssen E, Kim J, et al. A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 2003;77:285-93.
22. Evans AJ, Pinder SE, Ellis IO, et al. Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease? J Med Screen 2001;8:149-51.
23. Office of National Statistics. Incidence, mortality and population estimates. 2003. London, HMSO.
24. StataCorp. Stata Version 8.2 for Windows. 31-10-2003. Texas, USA, StataCorp.
25. Clayton D, Schifflers E. Models for temporal variation in cancer rates. II: Age-period-cohort models. Stat Med 1987;6:469-81.
26. Clayton D, Schifflers E. Models for temporal variation in cancer rates. I: Age-period and age-cohort models. Stat Med 1987;6:449-67.
27. Morrison AS. Early detection: sensitivity and lead time. In: Screening in Chronic Disease. New York Oxford: Oxford University Press, 1992; pp 43-73.
28. Walter SD, Day NE. Estimation of the duration of a pre-clinical disease state using screening data. Am J Epidemiol 1983;118:865-86.
29. NHS breast screening programme. NHS Breast screening programme review 2000. 2000.
30. NHS breast screening programme. NHS Breast screening programme review 2001. 2001.
31. NHS breast screening programme. NHS Breast screening programme review 2002. 2002.
32. NHS breast screening programme. NHS Breast screening programme review 2003. 2003.
33. Quinn M, Allen E. Changes in incidence of and mortality from breast cancer in England and Wales since the introduction of screening. BMJ 1995;331:1391-5.
34. Evans WP, Starr AL, Bennos ES. Comparison of the relative incidence of impalpable invasive breast carcinoma and ductal carcinoma in situ in cancers detected in patients older and younger than 50 years of age. Radiology 1997;204:489-91.
35. Wazer DE, Gage I, Homer MJ, et al. Age-related differences in patients with nonpalpable breast carcinomas. Cancer 1996;78:1432-7.
36. Quinn M, Babbs P, Brock A, et al. Chapter 5: Breast. Cancer Trends in England and Wale 1950-1999. Norwich, UK: Office of National Statistics, 2001; pp 41-5.
37. Prior P, Woodman CBJ, Wilson ARM, et al. Reliability of underlying incidence rates for estimating the effect and efficiency of screening for breast cancer. J Med Screen 1996;3:119-22.
38. Hugget C. Review of the quality and comparability of data held by regional Cancer Registries. Bristol, UK: Bristol Cancer Epidemiology Unit incorporating the South West Cancer Registry, 1995.
39. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
40. Paci E, Duffy SW. Modelling the analysis of breast cancer screening programmes: sensitivity, lead time and predictive value in the Florence District Programme (1975-1986). Int J Epidemiol 1991;20:852-8.
41. Tabar L, Fagerberg G, Chen HH, et al. Efficacy of breast cancer screening by age. Cancer 1995;75:2507-17.
42. Chen HH, Tabar L, Fagerberg CJG, et al. Effect of breast cancer screening after age 65. J Med Screen 1995;2:10-4.
43. Tabar L, Vitak B, Chen HH, et al. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights From long-term follow-up. Radiol Clin North Am 2000;38:625-51.
44. Paci E, Duffy S, Giorgi D, et al. Population-based breast cancer screening programmes: estimates of sensitivity, overdiagnosis and early prediction of the benefit. In Duffy S, Hill C, Esteve J, eds. Quantitative methods for the evaluation of cancer screening. London: Arnold, 2001; pp 127-35.
45. Yen MF, Tabar L, Vitak B, et al. Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer 2003;39:1746-54.
46. Dean L, Geshchicter CF. Comedocarcinoma of the breast. Arch Surg 1938;36:225-34.
47. Hwang ES, Esserman LJ. Management of ductal carcinoma in situ. Surg Clin North Am 1999;79:1007-30, viii.
48. McReady DR. Ductal Carcinoma in Situ. In Souhami RL, Tannock I, Hohenberger P, Horiot JC, eds. Oxford Textbook of Oncology. Oxford: Oxford University Press, 2004; pp 1717-24.
49. Fentiman IS. Trials of treatment for non-invasive breast cancer. Recent Results Cancer Res 1998;152:135-42.
50. Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003;362:95-102.
51. Winchester DP, Strom EA. Standards for diagnosis and management of ductal carcinoma in situ (DCIS) of the breast. American College of Radiology. American College of Surgeons. College of American Pathologists. Society of Surgical Oncology. CA Cancer J Clin 1998;48:108-28.
52. Duffy SW, Tabar L, Vitak B, et al. The relative contributions of screen-detected in situ and invasive breast carcinomas in reducing mortality from the disease. Eur J Cancer 2003;39:1755-60.